FY2026 EPS Estimates for BMRN Cut by Cantor Fitzgerald

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Cantor Fitzgerald cut their FY2026 earnings estimates for BioMarin Pharmaceutical in a research report issued on Tuesday, October 28th. Cantor Fitzgerald analyst O. Brayer now forecasts that the biotechnology company will post earnings of $4.72 per share for the year, down from their prior forecast of $4.81. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $3.15 per share.

A number of other analysts have also recently weighed in on the company. Truist Financial reduced their price target on BioMarin Pharmaceutical from $90.00 to $80.00 and set a “buy” rating for the company in a research report on Tuesday. Stifel Nicolaus reduced their target price on BioMarin Pharmaceutical from $91.00 to $73.00 and set a “buy” rating for the company in a report on Tuesday. HC Wainwright decreased their target price on BioMarin Pharmaceutical from $60.00 to $55.00 and set a “neutral” rating for the company in a research report on Monday. Wells Fargo & Company dropped their price target on shares of BioMarin Pharmaceutical from $90.00 to $70.00 and set an “overweight” rating on the stock in a research report on Tuesday. Finally, Morgan Stanley reduced their price objective on shares of BioMarin Pharmaceutical from $104.00 to $98.00 and set an “overweight” rating for the company in a research note on Tuesday. Sixteen investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $90.70.

BioMarin Pharmaceutical Stock Up 0.1%

BMRN stock opened at $51.91 on Wednesday. The company has a current ratio of 4.83, a quick ratio of 3.60 and a debt-to-equity ratio of 0.10. The firm has a market cap of $9.97 billion, a PE ratio of 19.52, a PEG ratio of 0.68 and a beta of 0.33. BioMarin Pharmaceutical has a 1 year low of $51.10 and a 1 year high of $73.51. The company has a fifty day simple moving average of $54.88 and a 200 day simple moving average of $57.13.

Institutional Investors Weigh In On BioMarin Pharmaceutical

Hedge funds have recently made changes to their positions in the stock. V Square Quantitative Management LLC bought a new position in BioMarin Pharmaceutical during the second quarter valued at about $25,000. Quent Capital LLC bought a new stake in shares of BioMarin Pharmaceutical in the 3rd quarter worth approximately $28,000. Rise Advisors LLC acquired a new stake in shares of BioMarin Pharmaceutical during the 1st quarter worth approximately $30,000. Brooklyn Investment Group grew its holdings in shares of BioMarin Pharmaceutical by 2,250.0% during the 1st quarter. Brooklyn Investment Group now owns 564 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 540 shares in the last quarter. Finally, Hantz Financial Services Inc. increased its position in shares of BioMarin Pharmaceutical by 480.2% during the second quarter. Hantz Financial Services Inc. now owns 1,056 shares of the biotechnology company’s stock valued at $58,000 after purchasing an additional 874 shares during the period. Institutional investors own 98.71% of the company’s stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.